share_log

博济医药(300404.SZ):获得药物临床试验批准通知书

Boji Medical Technology (300404.SZ): Received the notice of approval for clinical drug trials.

Gelonghui Finance ·  Dec 24, 2024 04:02

On December 24, Gelonghui reported that Boji Medical Technology (300404.SZ) announced its collaboration with Guangdong Gumadi Health Technology Co., Ltd. to develop and jointly apply for the "TBA Tablets," which have obtained the clinical trial approval notice issued by the National Medical Products Administration. TBA is a new, structurally defined compound with pharmacological effects and clinical value, classified as a first-class innovative drug not yet marketed domestically or internationally, with a proposed indication for drug-resistant tuberculosis. Tuberculosis is a chronic and deadly infectious disease that spreads globally, primarily caused by the Mycobacterium tuberculosis. TBA acts on QcrB in the electron transport chain of the mycobacterium, inhibiting its respiratory function.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment